Posts tagged ‘Lung Cancer Market Analysis’

Today marks a year since we put up a paywall on Biotech Strategy Blog. While we were sorry to have to restrict access in this way, our decision reflects what is happening in the wider digital media arena, it’s simply not possible to go to conferences and generate quality content for free!

It was Warren Buffett who said, “Price is what you pay, value is what you get” and that’s how we feel about charging for access to Premium Content on the blog.

When we put a paywall up on the blog last September, many thought it would not last. All those who bet on its early demise are still waiting 😉

What the paywall has done is create an exclusive club that have access to our insights and analysis. Other traditional media organizations are now following suit, by charging a membership fee for premium access.

There is a wealth of free data on the Internet, and lots of media folk do a good job of sharing or curating this, but raw data is not intelligence, nor do they tell you anything about context or meaning. Insights also require knowledge, expertise and thought to generate.

Journalism and digital media are going through a revolution as those who create original content seek to get paid for it. We are part of that vanguard. So this post is a big thank you for all our subscribers from around the world who have supported our initiative.

Our thanks also to Tinypass, who as our technology partner, creates the paywall and administers the payment processing system. We could not have achieved the success we have had without them.

Year in Review:

Looking back at this year, we’ve covered remotely or on site 10 conferences or scientific meetings:

By my calculation we’ve written approximately 120 premium content posts of the past year, so the cost per post at the current annual rate is about $10. Those who signed up for special offers got them for even less.

So thanks to everyone who has supported us over the past year, we greatly appreciate you being part of the journey with us. We look forward to welcoming new subscribers over the coming year.

For a limited time only (until end of October) we are offering a special anniversary offer where you can lock in your rate for 2 years. Just click on any post and scroll down to sign up in the box under the post.

CO-1686 is a third-generation EGFR inhibitor with early data showing that is effective in many non-small cell lung cancer (NSCLC) patients who have developed acquired resistance to existing EGFR TKIs.

There are currently no approved treatments for patients who develop a T790 mutation. This unmet medical need offers a sizeable market opportunity as the commercial landscape currently stands.

Clovis, however, are in a race to market with AstraZeneca, who also have an exciting new drug in development, AZD9291. Preliminary data has shown the agent to also be effective in NSCLC patients with the T790M mutation.

Both companies presented data at the World Lung Conference in Sydney at the end of October last year for their phase 1 trials.

As to which company will get to market first and which product is the best, the race to market is now too close to call and we don’t yet have enough data to compare the merits of the compounds but the JP Morgan Healthcare conference did offer insights.